RyR1-mediated Ca <sup>2+</sup> -induced Ca <sup>2+</sup> release plays a negligible role in excitation–contraction coupling of normal skeletal muscle

T Takuya Kobayashi (Kansai Medical University, Hirakata, Japan.) T Toshiko Yamazawa (Core Research Facilities, Research Center for Medical Sciences, The Jikei University School of Medicine) N Nagomi Kurebayashi (Department of Pharmacology, Juntendo University School of Medicine) M Masato Konishi (Department of Pharmacology, Juntendo University School of Medicine) J Jun Tanihata (Department of Cell Physiology, The Jikei University School of Medicine) M Masami Sugihara (Department of Clinical Laboratory Medicine, Juntendo University Graduate School of Medicine) Y Yoshifumi Miki (Core Research Facilities, Research Center for Medical Sciences, The Jikei University School of Medicine) S Satoru Noguchi (Department of Neuromuscular Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry) Y Yukiko U. Inoue (Department of Biochemistry and Cellular Biology, National Institute of Neuroscience, National Center of Neurology and Psychiatry) T Takayoshi Inoue (Department of Biochemistry and Cellular Biology, National Institute of Neuroscience, National Center of Neurology and Psychiatry) T Takashi Sakurai (Department of Pharmacology, Juntendo University School of Medicine) T Takashi Murayama (Department of Pharmacology, Juntendo University School of Medicine)

Abstract

Type 1 ryanodine receptor (RyR1) is a Ca 2+ release channel in the sarcoplasmic reticulum in skeletal muscle. In excitation–contraction (E-C) coupling, RyR1 opens by depolarization of transverse tubule membrane via physical interaction with dihydropyridine receptor, which is referred to as depolarization-induced Ca 2+ release (DICR). RyR1 can also be gated via Ca 2+ -induced Ca 2+ release (CICR), in which binding of Ca 2+ directly opens the channel. Thus, RyR1 has two Ca 2+ release modes; DICR and CICR, but the physiological role of CICR has been a matter of debate: whether CICR can amplify Ca 2+ signals in E-C coupling. To address this issue, we created a mouse model carrying a mutation in the Ca 2+ -binding site in RyR1 (RyR1-E3896A), which selectively inhibits CICR. Surprisingly, the homozygous RyR1-E3896A mice show no appreciable changes in E-C coupling, ex vivo muscle contraction, in vivo muscle performance, or muscle fiber type. Gain-of-function mutations in RyR1 cause malignant hyperthermia (MH), which is a lethal disease triggered by inhalational anesthetics. The E3896A mutation conferred resistance to isoflurane-induced MH episodes and severe heat stroke triggered by environmental heat stress. Our data suggest that RyR1-mediated CICR plays a negligible role in E-C coupling of normal skeletal muscle but may increase the risk for muscle diseases when excessively activated.

Article Details

Volume / Issue Vol. 122, Issue 34
Published August 26, 2025
ISSN 0027-8424
Publisher National Academy of Sciences

Authors (12)

T

Takuya Kobayashi

Kansai Medical University, Hirakata, Japan.

T

Toshiko Yamazawa

Core Research Facilities, Research Center for Medical Sciences, The Jikei University School of Medicine

N

Nagomi Kurebayashi

Department of Pharmacology, Juntendo University School of Medicine

M

Masato Konishi

Department of Pharmacology, Juntendo University School of Medicine

J

Jun Tanihata

Department of Cell Physiology, The Jikei University School of Medicine

M

Masami Sugihara

Department of Clinical Laboratory Medicine, Juntendo University Graduate School of Medicine

Y

Yoshifumi Miki

Core Research Facilities, Research Center for Medical Sciences, The Jikei University School of Medicine

S

Satoru Noguchi

Department of Neuromuscular Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry

Y

Yukiko U. Inoue

Department of Biochemistry and Cellular Biology, National Institute of Neuroscience, National Center of Neurology and Psychiatry

T

Takayoshi Inoue

Department of Biochemistry and Cellular Biology, National Institute of Neuroscience, National Center of Neurology and Psychiatry

T

Takashi Sakurai

Department of Pharmacology, Juntendo University School of Medicine

T

Takashi Murayama

Department of Pharmacology, Juntendo University School of Medicine